Chartwell Investment Partners LLC purchased a new position in Horizon Pharma PLC (NASDAQ:HZNP) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 83,138 shares of the biopharmaceutical company’s stock, valued at approximately $2,197,000.
Several other large investors also recently bought and sold shares of the company. Campbell Newman Asset Management Inc. lifted its holdings in shares of Horizon Pharma by 62.7% in the first quarter. Campbell Newman Asset Management Inc. now owns 30,685 shares of the biopharmaceutical company’s stock valued at $811,000 after purchasing an additional 11,821 shares in the last quarter. Huntington National Bank increased its position in shares of Horizon Pharma by 817.6% in the first quarter. Huntington National Bank now owns 14,976 shares of the biopharmaceutical company’s stock valued at $396,000 after acquiring an additional 13,344 shares during the last quarter. Tibra Equities Europe Ltd acquired a new stake in shares of Horizon Pharma in the first quarter valued at about $418,000. Geode Capital Management LLC increased its position in shares of Horizon Pharma by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 1,935,457 shares of the biopharmaceutical company’s stock valued at $37,818,000 after acquiring an additional 158,342 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Horizon Pharma in the fourth quarter valued at about $46,493,000. Institutional investors and hedge funds own 82.01% of the company’s stock.
In other news, EVP Geoffrey M. Curtis sold 10,080 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $21.21, for a total value of $213,796.80. Following the transaction, the executive vice president now owns 35,367 shares of the company’s stock, valued at $750,134.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Geoffrey M. Curtis sold 8,835 shares of the company’s stock in a transaction that occurred on Tuesday, February 5th. The shares were sold at an average price of $23.15, for a total value of $204,530.25. Following the completion of the transaction, the executive vice president now directly owns 32,202 shares in the company, valued at approximately $745,476.30. The disclosure for this sale can be found here. 3.90% of the stock is owned by insiders.
Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.13. The firm had revenue of $355.50 million for the quarter, compared to the consensus estimate of $334.22 million. Horizon Pharma had a positive return on equity of 34.09% and a negative net margin of 6.34%. The business’s revenue was up 29.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.29 earnings per share. On average, analysts anticipate that Horizon Pharma PLC will post 1.7 earnings per share for the current fiscal year.
A number of analysts recently issued reports on the company. Zacks Investment Research raised Horizon Pharma from a “sell” rating to a “hold” rating in a research report on Friday, January 25th. BMO Capital Markets lifted their target price on Horizon Pharma to $29.00 and gave the company a “market perform” rating in a research report on Thursday, April 4th. They noted that the move was a valuation call. Piper Jaffray Companies set a $33.00 target price on Horizon Pharma and gave the company a “buy” rating in a research report on Thursday, April 4th. Cantor Fitzgerald lifted their target price on Horizon Pharma from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, BidaskClub downgraded Horizon Pharma from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 20th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $30.73.
About Horizon Pharma
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Article: Buyback
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.